Thyroid Adenoma
ICD-10 E04.1 · ICD-11 2F37.Y.2

Treatment of Thyroid Adenoma: Solid Benign Nodule with Local Compression Symptoms

Clinical Scenario

This protocol applies to patients with a solid benign thyroid nodule that is producing local compression symptoms. Unlike small, asymptomatic nodules managed by watchful waiting, this presentation carries a functional burden that warrants active intervention.

Why Solid Architecture Matters

The solid composition of the nodule is a key driver of management choice. Because thermal ablation procedures offer a geometric and predictable volume of tissue destruction, they are the first-line approach for solid thyroid lesions — distinguishing this scenario from predominantly cystic nodules, where a different technique class is preferred.

Treatment Approach (Overview)

A thermal-based minimally invasive procedure is the recommended first-line intervention for this solid, symptomatic nodule.

The full regimen — including technique selection, the conditions under which surgical resection is considered, and the complete clinical algorithm — is available in the structured protocol below.

Treatment Goals

Successful management is defined by a sustained, long-lasting decrease in nodule volume alongside meaningful improvement of local compression symptoms.

Nodule volume reduction Local symptom relief
Instant Access to Structured Evidence-Based Regimens
References
DOI: 10.1530/ETJ-23-0067

Consider TA for the treatment of solid benign thyroid nodules that cause local symptoms as an alternative to surgery and for cystic lesions that relapse after EA.

EA is preferred as an effective, safe, and inexpensive treatment for cystic (or predominantly cystic) symptomatic thyroid nodules while TA procedures, due to their geometric and predictable volume of tissue destruction, are the first-line treatment for solid thyroid lesions.

For diseases limited to one lobe, lobectomy/hemithyroidectomy is recommended.

MITs result in a relevant and long-lasting decrease of nodule volume (57–77% at 5 years) that is paralleled by improvement of local symptoms and disease-related quality of life.

View source ↗